-Cash runway extended into the fourth quarter of 2020 through judicious resource management- –XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated via non-dilutive support- -Conference call today at 4:30 p.m. Eastern Time– DUBLIN, Ireland, May 11, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV),...
Author: @admin
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection. NDA submission for this indication is...
Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference
DUBLIN, Ireland, May 11, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the BofA Securities 2020 Virtual Health...
Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020
DUBLIN, Ireland, May 08, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results after the close of the U.S. financial markets on Monday, May 11, 2020. Nabriva’s...
Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update
WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a business update. “We are very pleased with the continued progress made during the first quarter of...
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infections Findings indicate oral ibrexafungerp could potentially decrease length of hospital...
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020 Phase 2 trial shows superiority of rezafungin in time to clear deadly infection Seven abstracts highlight new data on influenza antiviral conjugates (AVCs) from Cloudbreak® antiviral platform SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology...
XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)
Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP DUBLIN, Ireland, May 05, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Open Forum Infectious Diseases, an official...
Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress Oxford, UK, and Cambridge, MA, US, April 30, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results for the fourth period* and eleven months ended...
Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress Oxford, UK, and Cambridge, MA, US, April 30, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results for the fourth period* and eleven months ended...